Fusion Antibodies PLC Belfast investor presentation
19 Marzo 2020 - 08:00AM
RNS Non-Regulatory
TIDMFAB
Fusion Antibodies PLC
19 March 2020
Fusion Antibodies plc
("Fusion")
Belfast investor presentation
As stated on 17 February 2020, Fusion Antibodies plc (AIM: FAB),
specialists in pre-clinical antibody discovery, engineering and
supply for both therapeutic drug and diagnostic applications ,
announced that it would hold a presentation for investors on
Monday, 6 April 2020 in Belfast City. The event was to be held
jointly by Fusion and Diaceutics PLC, the diagnostic
commercialisation company.
The decision has been made by the management teams of both
companies to postpone this event.
If you have any questions, please contact the team at Walbrook
PR on 0207 933 8780 or at fusion@walbrookpr.com .
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 150 humanisation projects for its international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster, with the optimal drug candidate and ultimately speed
up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$95.5 billion in 2017 and is forecast to surpass $174.2 billion in
2026, an increase at a CAGR of between 6.9 per cent. for the period
2018 to 2026. In 2018, seven of the world's ten top selling drugs
were antibody-based therapeutics with the combined annual sales of
these drugs exceeding $62 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABRGDXUDBDGGI
(END) Dow Jones Newswires
March 19, 2020 03:00 ET (07:00 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2023 a Mar 2024